These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 37053275)

  • 1. Endothelial Cell Dysfunction and Increased Cardiovascular Risk in Patients With Chronic Kidney Disease.
    Baaten CCFMJ; Vondenhoff S; Noels H
    Circ Res; 2023 Apr; 132(8):970-992. PubMed ID: 37053275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Uremic Toxins on Endothelial Dysfunction in Chronic Kidney Disease: A Systematic Review.
    Harlacher E; Wollenhaupt J; Baaten CCFMJ; Noels H
    Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of endothelial dysfunction in chronic kidney disease.
    Malyszko J
    Clin Chim Acta; 2010 Oct; 411(19-20):1412-20. PubMed ID: 20598675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The contribution of thyroid dysfunction on cardiovascular disease in patients with chronic kidney disease.
    Tatar E; Kircelli F; Ok E
    Atherosclerosis; 2013 Mar; 227(1):26-31. PubMed ID: 23206977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Most exposed: the endothelium in chronic kidney disease.
    Vila Cuenca M; Hordijk PL; Vervloet MG
    Nephrol Dial Transplant; 2020 Sep; 35(9):1478-1487. PubMed ID: 31071222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric CKD and cardiovascular disease.
    Safder O; Al sharif S; Kari JA
    Cardiovasc Hematol Disord Drug Targets; 2014; 14(3):177-84. PubMed ID: 24720458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Damage of the endothelial glycocalyx in chronic kidney disease.
    Padberg JS; Wiesinger A; di Marco GS; Reuter S; Grabner A; Kentrup D; Lukasz A; Oberleithner H; Pavenstädt H; Brand M; Kümpers P
    Atherosclerosis; 2014 Jun; 234(2):335-43. PubMed ID: 24727235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased cardiovascular risk in patients with chronic kidney disease.
    Vondenhoff S; Schunk SJ; Noels H
    Herz; 2024 Mar; 49(2):95-104. PubMed ID: 38416185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progenitor cells and vascular function are impaired in patients with chronic kidney disease.
    Jie KE; Zaikova MA; Bergevoet MW; Westerweel PE; Rastmanesh M; Blankestijn PJ; Boer WH; Braam B; Verhaar MC
    Nephrol Dial Transplant; 2010 Jun; 25(6):1875-82. PubMed ID: 20083473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protecting the endothelium: a new focus for management of chronic kidney disease.
    Diaz-Buxo JA; Woods HF
    Hemodial Int; 2006 Jan; 10(1):42-8. PubMed ID: 16441826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies.
    Xu S; Ilyas I; Little PJ; Li H; Kamato D; Zheng X; Luo S; Li Z; Liu P; Han J; Harding IC; Ebong EE; Cameron SJ; Stewart AG; Weng J
    Pharmacol Rev; 2021 Jul; 73(3):924-967. PubMed ID: 34088867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Vascular Endothelium in Chronic Kidney Disease: A Novel Target for Aerobic Exercise.
    Martens CR; Kirkman DL; Edwards DG
    Exerc Sport Sci Rev; 2016 Jan; 44(1):12-9. PubMed ID: 26509484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Moderate Aerobic Exercise Training on Endothelial Function and Arterial Stiffness in CKD Stages 3-4: A Randomized Controlled Trial.
    Van Craenenbroeck AH; Van Craenenbroeck EM; Van Ackeren K; Vrints CJ; Conraads VM; Verpooten GA; Kouidi E; Couttenye MM
    Am J Kidney Dis; 2015 Aug; 66(2):285-96. PubMed ID: 25960303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indoxyl Sulfate, a Uremic Endotheliotoxin.
    Lano G; Burtey S; Sallée M
    Toxins (Basel); 2020 Apr; 12(4):. PubMed ID: 32260489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelial dysfunction in chronic kidney disease: determinant of susceptibility to end-organ damage and therapeutic response.
    Ochodnicky P; Vettoretti S; Henning RH; Buikema H; Van Dokkum RP; de Zeeuw D
    J Nephrol; 2006; 19(3):246-58. PubMed ID: 16874683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelial function and cardiovascular events in chronic kidney disease.
    Hirata Y; Sugiyama S; Yamamoto E; Matsuzawa Y; Akiyama E; Kusaka H; Fujisue K; Kurokawa H; Matsubara J; Sugamura K; Maeda H; Iwashita S; Jinnouchi H; Matsui K; Ogawa H
    Int J Cardiol; 2014 May; 173(3):481-6. PubMed ID: 24703800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How do Uremic Toxins Affect the Endothelium?
    Cunha RSD; Santos AF; Barreto FC; Stinghen AEM
    Toxins (Basel); 2020 Jun; 12(6):. PubMed ID: 32575762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Vascular dysfunction in Cardiorenal Syndrome type 4].
    Sessa C; Granata A; Gaudio A; Xourafa A; Malatino L; Lentini P; Fatuzzo P; Rapisarda F; Castellino P; Zanoli L
    G Ital Nefrol; 2020 Feb; 37(1):. PubMed ID: 32068357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indoxyl sulfate - the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease.
    Kamiński TW; Pawlak K; Karbowska M; Myśliwiec M; Pawlak D
    BMC Nephrol; 2017 Jan; 18(1):35. PubMed ID: 28122514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asymmetric dimethylarginine and angiopoietin-like protein-2 are independent predictors of cardiovascular risk in pre-dialysis non-diabetic chronic kidney disease patients.
    Ashokachakkaravarthy K; Rajappa M; Parameswaran S; Satheesh S; Priyadarshini G; Mohan Raj PS; Revathy G; Priyadarssini M
    Int Urol Nephrol; 2020 Jul; 52(7):1321-1328. PubMed ID: 32409974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.